Propel Bio Management’s Milestone Pharmaceuticals MIST Stock Holding History

Propel Bio Management’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.96M	Buy	7,429,590 +3,311,269	+80%	+$5.29M	5.21%	6
2026 Q1	$5.08M	Hold	4,118,321	–	–	3.2%	9
2025 Q4	$8.32M	Sell	4,118,321 -1,006,569	-20%	-$2.17M	7.1%	5
2025 Q3	$10.2M	Buy	5,124,890 +3,333,333	+186%	+$5.86M	10.26%	4
2025 Q2	$3.48M	Buy	1,791,557 +340,000	+23%	+$453K	4.22%	7
2025 Q1	$1.16M	Buy	+1,451,557	New	+$2.89M	1.35%	13

Other funds holding MIST

PCM

Pavaki Capital Management Pueblo, Colorado $287M AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Propel Bio Management's MIST Position: Q2 2026 in Review

Propel Bio Management increased its Milestone Pharmaceuticals (MIST) stake by 80% in Q2 2026, buying an estimated $5.29M and bringing the position to 7,429,590 shares worth $9.96M. The position accounts for 5.21% of the portfolio, ranked #6.

Propel Bio Management first reported a position in MIST in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.2M in Q3 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

Propel Bio Management held 7,429,590 shares of Milestone Pharmaceuticals worth $9.96M as of Q2 2026.
Propel Bio Management bought 3,311,269 Milestone Pharmaceuticals shares in Q2 2026, an estimated $5.29M.
Milestone Pharmaceuticals made up 5.21% of Propel Bio Management's portfolio in Q2 2026, its #6 holding.
Propel Bio Management first reported a position in Milestone Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Propel Bio Management's Milestone Pharmaceuticals position peaked at $10.2M in Q3 2025.
78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.